Intermediate versus hard end points in clinical trials on hypertension

Guido Grassi

Intermediate versus hard end points in clinical trials on hypertension

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

The main features of randomized clinical trials performed in the field of hypertension treatment are reviewed, based either on the evaluation of clinical events or on the assessment of surrogate outcome measures. The advantages, limitations, and clinical relevance of each approach are highlighted.

Original language	English
Pages (from-to)	294-297
Number of pages	4
Journal	Current Hypertension Reports
Volume	7
Issue number	4
Publication status	Published - Aug 2005

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Cite this

@article{12fd1af2fa414a0b82d049cae4a3676a,

title = "Intermediate versus hard end points in clinical trials on hypertension",

abstract = "The main features of randomized clinical trials performed in the field of hypertension treatment are reviewed, based either on the evaluation of clinical events or on the assessment of surrogate outcome measures. The advantages, limitations, and clinical relevance of each approach are highlighted.",

author = "Guido Grassi",

year = "2005",

month = aug,

language = "English",

volume = "7",

pages = "294--297",

journal = "Current Hypertension Reports",

issn = "1522-6417",

publisher = "Current Medicine Group",

number = "4",

}

TY - JOUR

T1 - Intermediate versus hard end points in clinical trials on hypertension

AU - Grassi, Guido

PY - 2005/8

Y1 - 2005/8

N2 - The main features of randomized clinical trials performed in the field of hypertension treatment are reviewed, based either on the evaluation of clinical events or on the assessment of surrogate outcome measures. The advantages, limitations, and clinical relevance of each approach are highlighted.

AB - The main features of randomized clinical trials performed in the field of hypertension treatment are reviewed, based either on the evaluation of clinical events or on the assessment of surrogate outcome measures. The advantages, limitations, and clinical relevance of each approach are highlighted.

UR - http://www.scopus.com/inward/record.url?scp=24944494144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944494144&partnerID=8YFLogxK

M3 - Article

C2 - 16061049

AN - SCOPUS:24944494144

VL - 7

SP - 294

EP - 297

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 4

ER -

Intermediate versus hard end points in clinical trials on hypertension

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this